Fennec Pharmaceuticals Sees Strong Q2 Growth and Expands Global Reach

Fennec Pharmaceuticals ( (TSE:FRX) ) has shared an update.

Fennec Pharmaceuticals reported a strong second quarter of 2025 with net revenues of $9.7 million, marking a 33% increase from the previous year. The company attributes this growth to its revamped go-to-market strategy and increased demand for PEDMARK in both large community practices and academic centers. The successful launch of PEDMARQSI in the UK and Germany, along with anticipated clinical trial results in Japan, highlight Fennec’s expanding global footprint. The addition of PEDMARK to a large national oncology group’s formulary and the issuance of a new U.S. patent further strengthen its market position and patent portfolio.

The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$15.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.

Spark’s Take on TSE:FRX Stock

According to Spark, TipRanks’ AI Analyst, TSE:FRX is a Neutral.

Fennec Pharmaceuticals shows strong revenue growth and improved cash flow, key for its industry. However, profitability issues and a weak balance sheet weigh down the score. Technical indicators and valuation reflect mixed signals, while positive earnings call sentiments provide some optimism. Addressing financial challenges will be crucial for future performance.

To see Spark’s full report on TSE:FRX stock, click here.

More about Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing treatments to prevent chemotherapy-induced hearing loss, particularly in pediatric patients. Their primary product, PEDMARK, is designed to prevent cisplatin-induced ototoxicity, and they are expanding their market presence in the U.S. and Europe.

Average Trading Volume: 796

Technical Sentiment Signal: Buy

Current Market Cap: C$350.8M

Learn more about FRX stock on TipRanks’ Stock Analysis page.